117693-41-1

Basic information

• Product Name: DesosaMinylazithroMycin
• Synonyms: DesosaMinylazithroMycin;Desosaminylazithromycin (15 mg);(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-Ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptaMethyl-11-[[3,4,6-trideoxy-3-(diMethylaMino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one;CP 66458;DesosaMinylazithroMyc;Azithromycin Impurity J(BP)
• CAS NO: 117693-41-1
• Molecular Formula: C₃₀H₅₈N₂O₉
• Molecular Weight: 590.78952
• Mol File: 117693-41-1.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 727.3±60.0 °C(Predicted)
• Appearance: /
• Density: 1.17±0.1 g/cm3(Predicted)
• PKA: 13.29±0.70(Predicted)
• CAS DataBase Reference: DesosaMinylazithroMycin(CAS DataBase Reference)
• NIST Chemistry Reference: DesosaMinylazithroMycin(117693-41-1)
• EPA Substance Registry System: DesosaMinylazithroMycin(117693-41-1)

Safety Data

• Hazardous Substances Data: 117693-41-1(Hazardous Substances Data)

Usage

Chemical Properties

Pale Green Solid

Uses

Different sources of media describe the Uses of 117693-41-1 differently. You can refer to the following data:
1. Descladinose Azithromycin is a metabolite of the semi-synthetic macrolide antibiotic Azithromycin (A927000).
2. Descladinose Azithromycin (Azithromycin EP Impurity J) is a metabolite of the semi-synthetic macrolide antibiotic Azithromycin (A927000).

Upstream product

• 83905-01-5 Zithromax(R) 

Downstream Products

• 922724-94-5 C₅₃H₇₈ClN₃O₁₀ 

Relevant articles and documents

Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives

Novel series of novel 3-O-arylalkylcarbamoyl descladinosylazithromycin derivatives with the 2′-O-acetyl and 11,12-cyclic carbonate groups, the 11,12-cyclic carbonate group and the 11-O-arylalkylcarbamoyl side chain, and 2′-O-arylalkylcarbamoyl descladinos

Synthesis and antibacterial evaluation of a series of 11,12-cyclic carbonate azithromycin-3-O-descladinosyl-3-O-carbamoyl glycosyl derivatives

A novel series of 11,12-cyclic carbonate azithromycin-3-O-descladinosyl-3-O-carbamoyl glycosyl derivatives were designed, synthesized, and evaluated for their antibacterial activities in vitro. Most of these compounds had significant antibacterial activity against seven kinds of susceptible strains. In particular, compound G1 exhibited the most potent activity against methicillin-resistant Streptococcus pneumoniae 943 (MIC: 1 μg/mL), Staphylococcus pneumoniae 746 (MIC: 2 μg/mL), Streptococcus pyogenes 447 (MIC: 8 μg/mL), and Escherichia coli 236 (MIC: 32 μg/mL), which were two-, four-, four-, four-, and eight-fold stronger activity than azithromycin, respectively. Additionally, compound G2 exhibited improved activity against methicillin-resistant Staphylococcus aureus MRSA-1 (MIC: 8 μg/mL), Streptococcus pneumoniae 943 (MIC: 2 μg/mL), Staphylococcus pneumoniae 746 (MIC: 2 μg/mL), and Escherichia coli 236 (MIC: 32 μg/mL), which were two-, two-, four-, and eight-fold better activity than azithromycin, respectively. As for methicillin-resistant Staphylococcus aureus MRSA-1, compound G6 presented the most excellent activity (MIC: 4 μg/mL), showing four-fold higher activity than azithromycin (MIC: 16 μg/mL) and erythromycin (MIC: 16 μg/mL). However, compared with other compounds, compounds G7 and G8 with the disaccharide side chain were observed the lower activity against seven strains.

Synthesis and Antibacterial Activity of New N-Alkylammonium and Carbonate-Triazole Derivatives within Desosamine of 14- and 15-Membered Lactone Macrolides

Desosamines of azithromycin (AZM) and clarithromycin (CLA) were modified by N-alkylation or nucleophilic substitution at the carbonyl/CuAAC sequence. Biological studies revealed a higher antibacterial potency of quaternary N-alkylammonium bromides of CLA as compared to AZM. SAR studies of CLA salts, including biological, conformation and molecular-docking analysis, enriched by physicochemical parameters, showed the importance of less bulky and unsaturated substituent for an efficient docking mode at the ribosomal tunnel and good antibacterial potency against clinical and standard Streptococcus pneumoniae and Streptococcus pyogenes strains (MICs 0.25 or 0.5 μg/mL). These CLA salts also have an at least threefold lower cytotoxicity than reference antibiotics at comparable antibacterial activity against the S. pneumoniae clinical strain. Differences in antibacterial effects noted for AZM and CLA salts bearing less bulky N-substituents can be better understood when their binding modes in the ribosomal tunnel are considered rather than their common low lipophilicity and excellent water solubility.

3 - O -aralkyl substituted RMB 15-azlactone derivative as well as preparation method and application thereof

The invention relates to the field of medicines, in particular to 3-O - aralkyl substituted RMB 15-azlactone derivatives as well as a preparation method and application thereof. 3 - O -arylalkyl-substituted RMB 15-azlactone-based derivatives having the structure of general formula I. In-flight R1 An aryl group or a substituted aryl group. R2 From hydrogen. Acetyl or benzoyl. The 3-O - aralkyl substituted RMB 15-azlactone derivative shows significant antibacterial activity on various gram-positive bacteria and gram-negative bacteria, and especially has good antibacterial activity on clinically isolated enterococcus faecium strain, methicillin-resistant staphylococcus aureus and penicillin-resistant staphylococcus aureus.